Clinical Research & News
Dr. Rubin's commitment to advancing pain medicine through active research participation.
Dr. Edward Rubin is an active participant in FDA clinical research — bringing cutting-edge treatments to Long Island patients before they reach widespread availability. He most recently served as an investigator on a Phase 2 multicenter trial for Halneuron, a novel therapy for chemotherapy-induced neuropathic pain. That study has now wrapped up — and the next trial is already in the works. His ongoing commitment to research helps ensure his patients have access to the most advanced, evidence-supported therapies available.
Most Recent Trial
Halneuron for Chemotherapy-Induced Neuropathic Pain (CINP)
Enrollment ClosedA randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy and safety of a single subcutaneous administration of Halneuron (HAL) in patients with neuropathic pain caused by platinum and/or taxane chemotherapy. Dr. Rubin is a participating investigator. Eligible patients must be ≥18 years old with confirmed CINP attributed to prior platinum or taxane chemotherapy, with no active disease progression.
View on ClinicalTrials.gov🔬 Stay Tuned for the Next Trial
Between studies, Dr. Rubin is already preparing the next research protocol. If you'd like to be considered for an upcoming trial — or think your condition might qualify — reach out and we'll keep you in mind.
Contact Us